Sarcopenia Treatment Market Report 2024 - Sarcopenia Treatment Market Size And Growth

"The Business Research Company recently released a comprehensive report on the Global Sarcopenia Treatment Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.

According to The Business Research Company's, The sarcopenia treatment market size has grown strongly in recent years. It will grow from $3.30 billion in 2023 to $3.52 billion in 2024 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to aging population, awareness and diagnosis, lifestyle changes, public health initiatives, regulatory approvals.

The sarcopenia treatment market size is expected to see strong growth in the next few years. It will grow to $4.44 billion in 2028 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to personalized medicine, nutritional interventions, digital health platforms, patient education and empowerment, global health initiatives. Major trends in the forecast period include personalized therapies, emergence of novel drug classes, digital health integration, collaborative research initiatives, research and development.

Get The Complete Scope Of The Report @
https://www.thebusinessresearchcompany.com/report/sarcopenia-treatment-global-market-report

Market Drivers and Trends:
The rise in malnutrition is expected to propel the growth of the sarcopenia treatment market going forward. Malnutrition refers to deficiencies, excesses, or imbalances in a person's intake of energy and nutrients, covering both undernutrition and overweight, obesity, and diet-related noncommunicable diseases. Sarcopenia treatment helps address the coexisting conditions of malnutrition and sarcopenia in older adults through interventions such as nutritional therapy and exercise, aiming to improve muscle mass, strength, and overall nutritional status. For instance, in December 2023, according to a report published by the World Health Organization (WHO), a Switzerland-based United Nations (UN) organization, malnutrition remains a significant global health challenge, with an estimated 462 million underweight and 149 million children under 5 suffering from stunting in 2022. Therefore, the rise in malnutrition is driving the growth of the sarcopenia treatment market.

Major companies operating in the sarcopenia treatment market are increasing their focus on development of multiple advance clinical option study to adhere with better treatment option. A clinical study is a systematic investigation conducted on human subjects to evaluate the safety, efficacy, and/or outcomes of a medical intervention. For instance, in September 2023, Biophytis, a France-based biotechnology company, announced the Food and Drug Administration (FDA) authorization to initiate the SARA-31 Phase 3 study in sarcopenia. The study aims to evaluate the efficacy and safety of Sarconeos (BIO101) in the treatment of sarcopenic patients at risk of motor disability. This study demonstrates a significant advancement in technological and pharmaceutical treatment approaches, offering potential efficacy and safety benefits for severe sarcopenic patients. It is the first-ever phase 3 study in sarcopenia and has received FDA authorization. The study will include around 900 patients aged over 65 with sarcopenia, low walking speed, and low hand grip strength. The primary endpoint will be the assessment of the risk of major mobility disability (MMD), walking speed, hand grip strength, and patient-reported quality of life.

Key Benefits for Stakeholders:
• Comprehensive Market Insights: Stakeholders gain access to detailed market statistics, trends, and analyses that help them understand the current and future landscape of their industry.
• Informed Decision-Making: The reports provide crucial data that support strategic decisions, reducing risks and enhancing business planning.
• Competitive Advantage: With in-depth competitor analysis and market share information, stakeholders can identify opportunities to outperform their competition.
• Tailored Solutions: The Business Research Company offers customized reports that address specific needs, ensuring stakeholders receive relevant and actionable insights.
• Global Perspective: The reports cover various regions and markets, providing a broad view that helps stakeholders expand and operate successfully on a global scale.

Ready to Dive into Something Exciting? Get Your Free Exclusive Sample of Our Research Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=13926&type=smp

Major Key Players of the Market:
Pfizer Inc., F-Hoffmann La-Roche, Merck Sharp & Dohme Corp. (Merck & Co.), AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Abbott Laboratories Inc., GlaxoSmithKline plc, Eli Lilly and Company, BASF SE, Nestle Health Science, Haleon Group of Companies, Regeneron Pharmaceuticals Inc., DSM, American Way (Amway) Corporation, Perrigo Company PLC, Intas Pharmaceuticals Ltd, Zydus Lifesciences, Fermenta Biotech Limited, Metagenics LLC, Ion Labs Inc., Makers Nutrition LLC, NutraScience Labs, AstaReal AB, NutraPak USA, BioThrive Sciences, Wellona Pharma, Healing Pharma India Pvt. Ltd., Nutrafill

Sarcopenia Treatment Market 2024 Key Insights:
• The Major Key Players of the Market:
Pfizer Inc., F-Hoffmann La-Roche, Merck Sharp & Dohme Corp. (Merck & Co.), AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Abbott Laboratories Inc., GlaxoSmithKline plc, Eli Lilly and Company, BASF SE, Nestle Health Science, Haleon Group of Companies, Regeneron Pharmaceuticals Inc., DSM, American Way (Amway) Corporation, Perrigo Company PLC, Intas Pharmaceuticals Ltd, Zydus Lifesciences, Fermenta Biotech Limited, Metagenics LLC, Ion Labs Inc., Makers Nutrition LLC, NutraScience Labs, AstaReal AB, NutraPak USA, BioThrive Sciences, Wellona Pharma, Healing Pharma India Pvt. Ltd., Nutrafill is expected to grow toSarcopenia Treatment Market 2024 Key Insights:
• Surge In Malnutrition Boosts Sarcopenia Treatment Market Growth
• Biophytis Receives FDA Authorization For Groundbreaking SARA-31 Phase 3 Study
• North America was the largest region in the sarcopenia treatment market in 2023.

We Offer Customized Report, Click @
https://www.thebusinessresearchcompany.com/customise?id=13926&type=smp

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ"

This release was published on openPR.